Sodium‐glucose cotransporter‐2 inhibitors in heart failure: an updated meta‐analysis by Yang Cao, Pengxiao Li, Yi Li, Yaling Han

Subjects: Get full text

Uninephrectomy and sodium‐glucose cotransporter 2 inhibitor administration delay the onset of hyperglycemia by Yuri Sakai Ishizaki, Masao Kikuchi, Koichi Kaikita, Shouichi Fujimoto

Get full text

Unmasking of normocalcemic primary hyperparathyroidism after sodium-glucose cotransporter-2 inhibitor initiation by Christodoulos Dolapsakis, Emmanouil Karofylakis, Stamatios Chalvatzis

“…Sodium-glucose cotransporter-2 (SGLT2) inhibitors have complex interactions with bone metabolism, including an increase in parathyroid hormone (PTH) levels. …”
Get full text

Sodium‐Glucose Cotransporter 2 Inhibitors for Mesenchymal–Epithelial Transition Inhibitor‐Induced Edema by Takuya Oyakawa, Keita Miura, Nao Muraoka, Kei Iida, Ayano Fujita, Tateaki Naito, Toshiaki Takahashi

“…ABSTRACT The effects of sodium‐glucose cotransporter 2 (SGLT2) inhibitors on mesenchymal‐epithelial transition factor (MET) inhibitor‐induced edema remain unclear. …”
Get full text

The first experience with sodium‐glucose cotransporter 2 inhibitor for the treatment of systemic right ventricular failure by Anastasia D. Egorova, Marieke Nederend, Laurens F. Tops, Hubert W. Vliegen, Monique R.M. Jongbloed, Philippine Kiès

“…Pharmacological options for the treatment of sRV failure are poorly defined and no solid recommendations are made in the most recent guidelines. Sodium‐glucose cotransporter 2 (SGLT‐2) inhibitors are a new class of antihyperglycaemic drugs that have been demonstrated to significantly reduce the risk of worsening heart failure and death from cardiovascular causes in patients with chronic heart failure with reduced left ventricular ejection fraction, yet no data are available in sRV patients. …”
Get full text

Focusing on Sodium Glucose Cotransporter-2 and the Sympathetic Nervous System: Potential Impact in Diabetic Retinopathy by Lakshini Y. Herat, Vance B. Matthews, P. Elizabeth Rakoczy, Revathy Carnagarin, Markus Schlaich

“…Presently, sodium glucose cotransporter-2 (SGLT2) inhibitors may offer a novel therapy beyond simple glucose lowering. …”
Get full text

Potent Oral Hypoglycemic Agents for Microvascular Complication: Sodium-Glucose Cotransporter 2 Inhibitors for Diabetic Retinopathy by Eun Hyung Cho, Se-Jun Park, Seongwook Han, Ji Hun Song, Kihwang Lee, Yoo-Ri Chung

“…The purpose of this study was to investigate the effects of sodium-glucose cotransporter 2 inhibitors (SGLT2i) on the progression of diabetic retinopathy (DR) in patients with type 2 diabetes. …”
Get full text

Feasibility and Safety of Sodium Glucose Cotransporter-2 Inhibitors in Adults with Heart Failure after the Fontan Procedure by Jun Muneuchi, Yuichiro Sugitani, Masaru Kobayashi, Hiroki Ezaki, Hiromu Yamada, Mamie Watanabe

“…Sodium glucose cotransporter-2 (SGLT-2) inhibitors have been widespread in patients with heart failure; however, there is little information regarding its feasibility and safety among patients after the Fontan procedure. …”
Get full text

Effect of sodium glucose cotransporter-2 inhibitors (SGLT-2is) on the clinical outcomes of patients with diabetic atrial fibrillation by Selim Aydemir, Sidar Şiyar Aydın, Emrah Aksakal, Onur Altınkaya, Murat Özmen, Oğuzhan Birdal

“…The importance of sodium glucose cotransporter-2 inhibitors (SGLT-2is) in treating DM has increased significantly in recent years. …”
Get full text

The influence of the pharmacodynamic properties of drugs on indications for their use: Sodium-glucose cotransporter 2 inhibitors (SGLT2 inhibitors) by Denda Nikola I., Maletin Nemanja Z., Atanasković Marko B., Vučković Biljana A., Rašković Aleksandar L.

Get full text

Estimated glomerular filtration rate dip at sodium-glucose cotransporter 2 inhibitor initiation: Implications for practice in chronic kidney disease by Ying Fan, Niansong Wang, Sihan Zhou

Get full text

Sodium-Glucose Cotransporter-2 (SGLT-2) Attenuates Serum Uric Acid (SUA) Level in Patients with Type 2 Diabetes by Mazhar Hussain, Asim Elahi, Abid Hussain, Javed Iqbal, Lubna Akhtar, Abdul Majid

“…The goal of this study was to compare the effect of sodium-glucose cotransporter-2 (SGLT-2) inhibitors dapagliflozin and empagliflozin on serum uric acid (SUA) levels in patients with type 2 diabetes against traditional oral antihyperglycemic drugs (OADs). …”
Get full text

Association of sodium–glucose cotransporter-2 inhibitors with mortality across the spectrum of myocardial infarction: a systematic review and meta-analysis by Michele Maremmani, Ramin Ebrahimi, Marco Centola, Felice Achilli, Valentina Capone, Eduardo Bossone, Christian Templin, Davide Di Vece

Subjects: “…Sodium–glucose cotransporter-2 inhibitors…”
Get full text

Evaluating the overall renal outcomes of sodium-glucose cotransporter-2 (SGLT2) inhibitors in patients with chronic kidney disease (CKD) by Min-Jia Cao, Ting-Ting Liang, Li Xu, Fang-Hong Shi

“…Abstract Background Our meta-analysis fills gaps by assessing sodium-glucose cotransporter-2 (SGLT2) inhibitors’ renal outcomes in chronic kidney disease (CKD) patients including long-term effects and the subgroup analyses of estimated glomerular filtration rate (eGFR) values and follow-up times. …”
Get full text

Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Urine Albumin to Creatinine Ratio in Type 2 Diabetes Mellitus Patients and Medication Care by Dong-Dong Wang, Cun Zhang, Yang Yang, Su-Mei He, Ping Zhu, Xiao Chen

“…The purpose of this study was to explore the effects of sodium-glucose cotransporter-2 (SGLT-2) inhibitors on urine albumin to creatinine ratio (UACR) in type 2 diabetes mellitus (T2DM) patients and to recommend appropriate medication care scheme. …”
Get full text

Sodium-glucose cotransporter-2 inhibitors increase urinary tract infections?—a cross sectional analysis of a nationwide Japanese claims database by Go Anan, Daisuke Kikuchi, Kenji Omae, Takuo Hirose, Kouji Okada, Takefumi Mori

Subjects: “…sodium-glucose cotransporter-2 inhibitor…”
Get full text

The impact of sodium-glucose cotransporter-2 inhibitors on the incidence, therapy, and outcomes of fournier gangrene: insights from a systematic review of case reports by Yufi Aulia Azmi, Firas F. Alkaff, Kevin Muliawan Soetanto, Soetojo Wirjopranoto, Maarten J. Postma, Abdul Khairul Rizki Purba

“…Abstract Background The clinical characteristics, therapy, and outcome of Fournier Gangrene (FG) in patients using sodium-glucose cotransporter-2 inhibitors (SGLT2i) were examined in this systematic review. …”
Get full text

Fournier Gangrene Associated with Sodium-Glucose Cotransporter-2 Inhibitors: A Pharmacovigilance Study with Data from the U.S.... by Yang Hu, Ziyu Bai, Yan Tang, Rongji Liu, Bin Zhao, Jian Gong, Dan Mei

“…Food and Drug Administration (FDA) released a safety warning of Fournier gangrene (FG), a rare but serious adverse effect of sodium-glucose cotransporter-2 (SGLT2) inhibitors in August 2018. …”
Get full text

Trends in prescribing sodium‐glucose cotransporter 2 inhibitors for individuals with type 2 diabetes with and without cardiovascular‐renal disease in South Korea, 2015–2021 by Kyoung Hwa Ha, Soyoung Shin, EunJi Na, Dae Jung Kim

“…ABSTRACT Background This study evaluates shifts in oral glucose‐lowering drug prescription patterns and the adoption of sodium‐glucose cotransporter 2 inhibitors (SGLT2is) in South Korea. …”
Get full text

Sodium-glucose cotransporter-2 inhibitors improve liver enzymes in patients with co-existing non-alcoholic fatty liver disease: a systematic review and metanalysis by Waseem Amjad, Adnan Malik, Waqas Qureshi, Brittany Dennis, Mirrah Mumtaz, Rabbia Haider, Shakeel Jamal, Faisal Jaura, Aijaz Ahmed

Get full text